Clinical follow-up
The results of the 12-month follow-up are presented in Table 3 and Figure 1. In the DAPT group, OAC with VKA and NOAC was restarted in 14 (6.4%) patients. Reasons were ischemic stroke (n=5), pulmonary embolism/deep vein thrombosis (n=5), thrombus on the ventricular electrode of an indwelling implantable cardioverter-defibrillator (n=1), significant peri-device flow (n=2), and DRT (n=1). DAPT was prolonged to 12 months in nine (4.1%) patients due to concomitant coronary heart disease. In the ACT group, 17 (5.6%) patients resumed oral anticoagulation with VKA or NOACs. Reasons were ischemic stroke (n=8), pulmonary embolism/deep vein thrombosis (n=6) and DRT (n=3). Ten (3.3%) were still on DAPT for coronary heart disease.